Cognizin Ingredient Shown to Improve Focus, Concentration and Memory

26 Jan 2011 --- A six-week study conducted at McLean Hospital, a Harvard Medical School affiliate located in Belmont, Mass., was designed to measure and visualize the functional effects of Cognizin on various facets of brain function.

1/26/2011 --- Deborah Yurgelun-Todd, Ph.D., Director of the Cognitive Neuroimaging Laboratory at The Brain Institute at The University of Utah, presented new scientific data on Kyowa Hakko's branded brain health ingredient Cognizin at the SupplySide Science Tour held January 24, 2011, in Irvine, Calif. She highlighted results of a six-week study conducted at McLean Hospital, a Harvard Medical School affiliate located in Belmont, Mass., designed to measure and visualize the functional effects of Cognizin on various facets of brain function.

On the first day of testing, 16 healthy subjects aged 40 - 60 years underwent functional Magnetic Resonance Imaging (fMRI) while completing both the Stroop task, which is designed to measure attention and reaction time, and the Morris Water Maze task, which examines spatial memory. Subjects were then given a daily oral dose of either 500 or 2000 mg of Cognizin for six weeks before a second imaging protocol was conducted.

After completion of the second fMRI imaging test, increased activation was seen during completion of the Stroop interference task. This was accompanied by improved accuracy in generating correct responses. 

These results indicated that use of Cognizin resulted in a better, more accurate performance, accompanied by increased brain metabolism. 
Increased activation was seen during completion of the second Water Maze test as well. This was accompanied by increased time spent in the correct quadrant. These results indicated that use of Cognizin resulted in better spatial memory retrieval, in addition to increased brain metabolism. Results were nearly identical for individuals receiving 500 mg and 2000 mg of Cognizin, confirming that statistically significant improvements in attention, focus, memory and recall can be achieved at dosing levels of 500 mg.

"Neuroimaging data demonstrated increased regional brain activation, which was related to increased concentration, greater ability to focus and improved accuracy on cognitive tasks after subjects received Cognizin," noted Dr. Yurgelun-Todd. "Greater performance on a spatial memory task was also observed."

Cognizin Citicoline is a natural, water-soluble brain health ingredient, and is a well-established part of the cognitive health category. Vast research indicates this safe and effective branded compound helps protect neural tissue from free radical damage. It also supports brain performance by enhancing metabolism and healthy activity. Unlike other single-action ingredients for brain health, Cognizin is multi-functional. It has shown to benefit individuals affected by memory loss, mood/behavioral disorders, mild cognitive impairment and certain vision disorders.

Related Articles

Food Ingredients News

RIMFROST to Launch Ultra-High Phospholipid Krill Extract

02 Oct 2015 --- RIMFROST AS will be launching ultra-high phospholipid SUBLIME krill extract at the upcoming SupplySide West Expo in October. Strategically, the Norwegian Antarctic krill oil player reframes the market, focuses on new consumer benefits and positions itself outside the omega-3 category.

Food Ingredients News

New Clinical Study Confirms Green Oat Ingredient Efficacy on Cognitive Performance

29 Sep 2015 --- A successful clinical study confirms previously demonstrated benefits of Neuravena on acute improvement of cognitive function, showing efficacy for an 800 mg dose. Neuravena is produced and marketed by Frutarom BU Health, and will be featured at Supply Side West.

Health & Nutrition News

Study Suggests Improving Blood Sugar Control Could Help Prevent Dementia

21 Sep 2015 --- A study of 350,000 patients with type 2 diabetes shows that those with poor blood sugar control have 50% higher risk of being admitted to hospital in future for dementia as those with good control. The research, which suggests improving blood sugar control could prevent many cases of dementia, is by Dr Aidin Rawshani, National Diabetes Register and Institute of Medicine, Gothenburg, Sweden, and colleagues, and is presented at this year's annual meeting of the European Association for the Study of Diabetes (EASD) in Stockholm.

Health & Nutrition News

Modulation of Brain Cholesterol: a New Line of Research in Alzheimer’s Disease Treatment?

18 Sep 2015 --- We have known for some years that Alzheimer’s disease is characterized by two types of lesions, amyloid plaques and degenerated tau protein. Cholesterol plays an important role in the physiopathology of this disease. Two French research teams (Inserm/CEA/University of Lille/University of Paris-Sud) have just shown, in a rodent model, that over expressing an enzyme that can eliminate excess cholesterol from the brain may have a beneficial action on the tau component of the disease, and completely correct it. This is the first time that a direct relationship has been shown between the tau component of Alzheimer’s disease and cholesterol. This work is published in the September 2015 issue of Human Molecular Genetics.

More Articles